At Nationwide Children’s Hospital, I worked on mouse nervous system tumor models (CNS and MPNST) to tease out the pre-clinical efficacy and safety studies using oncolytic virus and exosome-based therapies as well as demonstration of the mechanism of action of gene therapies through in vitro and in vivo pre-clinical proof of concept studies. I worked on designing and validation of the virus-targeting constructs and then generating and molecular confirmation of the oncolytic virus first in vitro and then in vivo on mouse models (both flank and intracranial). The effects are analyzed by immunophenotypic analyses of the lymphoid and myeloid infiltrates by flow cytometry, Cytof or single cell sequencing. Another aspect of my research has been using exosomes as target gene delivery vehicles (packed with cytokines or drugs or AAV) on the mouse models and validating the effects. The studies have resulted in the following patent:
“Extracellular Vesicle (EVs) for Therapeutic Delivery to Tumors Delivery”, Provisional patent applied for “Loading Extracellular Vesicles with cargo”., NCH Ref #2020-100 “TARGET-ED”
My primary research work at the Ohio State University focused on the molecular and biochemical behavior of drug resistance in ovarian clear cell cancer and ovarian cancer therapeutics. I have been working in the field of cancer research for more than 8 years. My research interest was directed towards: i) Dissecting the role of STAT3 and targeting ovarian cancer; ii) the role of TMEM205 in imparting drug resistance to ovarian clear cell cancer and iii) the use and mechanism of action of novel synthetic curcumin analog compounds for ovarian cancer therapy; iv) to elucidate the role of STAT3 and PIAS3 in the initiation and early tumorigenesis of HGSC v) utilizing oHSV virotherapy and deciphering the host-pathogen mechanisms involved in the same vi) analyzing the Role of STAT3 activation in the fallopian tube and development of ovarian HGSC and TMEM205 mediated chemoresistance in human ovarian clear cell carcinoma.
Mesenchymal Stem Cell based approaches to address ischemia/reperfusion and hypoxia associated cardiac damage
I also worked on various molecular, biochemical and physiological behavioral aspects of stem cells in order to make them more viable and effective in ischemia/reperfusion and hypoxia conditions during cardiac arrest. Another aspect of the work involved studying the molecular and cell signaling and crosstalk of human Lamin A/C gene and mutant lamin A/C genes at genomic and proteomic levels in congenital cardiac defect patients.
Developing a tunable light switch using Anabaena Sensory Rhodopsin (ASR)
The far-reaching goal of this research was to elucidate the function and molecular basis of interactions between the sensory rhodopsin form Anabaena (ASR) and its transducer, so as to decipher the biological function of this relatively less known protein. Site directed color tuning mutants were also developed which showed specific spectral features and have a potential to be developed into molecular switches. Since the above proteins resemble the human rhodopsin to a large extent, the far-reaching impact of this study is to help eye diseases related to partial or complete sight loss.
Technical Skills
Leadership skills
Lead, interpret, troubleshoot, supervise and present multiple cross-functional research drug discovery projects ranging from small molecule inhibitors, oncolytic viruses and exosome mediated cargo delivery